Navigation Links
Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower

The Food and Drug Administration (FDA) has granted approval to Mylan Technologies, Inc., for the first generic version of Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to treat patients suffering from severe chronic pain that cannot be managed with alternative analgesics. When applied to the skin, this patch technology delivers fentanyl, an opioid pain medication that is slowly absorbed into the body through the skin providing pain relief for up to three days (72 hours).

The agency's approval is expected to provide patients with access to a lower cost alternative of this pain management system. At the same time that FDA approved Mylan's generic product, it acted on several citizens' petitions requesting that FDA deny or delay approval of the product.

The original Fentanyl Transdermal System was approved in August 1990. It is currently approved for the management of chronic pain in patients who require continuous opioid analgesia for pain that cannot be managed by acetaminophen-opioid combinations, non-steroidal analgesics, or as needed dosing with short-acting opioids.

Fentanyl is currently a Schedule II controlled substance, which is the highest level of control for drugs with a recognized medical use. As a controlled substance in Schedule II of the Controlled Substances Act (CSA), Fentanyl also comes under the jurisdiction of the Drug Enforcement Administration (DEA), which administers the CSA. Schedule II drugs are subject to manufacturing quotas set by DEA with input on medical need from FDA, distribution tracking, import and export controls, registration of prescribers and dispensers, and written prescriptions without refills.


'"/>

Source:


Page: 1

Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding

Post Your Comments:
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlif...ort revealing that the last remaining population o...y due to the rising tide of poaching and habitat l... inform Russian officials of what needs to be done...iggest cat. , The report was releas...
(Date:11/24/2009)..., Md. (November 24, 2009) New research on bacteri...cosystems reveals predictable temporal patterns, s...ies as markers for monitoring climate change in th... the Proceedings of the National Academy of Scien...es in the six rivers shifted synchronously over ti...
(Date:11/23/2009)...n, D.C. The community-associated strain of the de...sistant to most common antibioticsposes a far grea...ing its way into hospitals, according to a study i...ses . , The new threat is easily picked up in f...nd has increased the overall burden of MRSA within...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Reward Yourself by Taking Your Dog to Obedience Training 58083 1Reward Yourself by Taking Your Dog to Obedience Training 58083 2Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 1Anthem Blue Cross and Blue Shield Awarded NCQAs Accreditation Status of Excellent 58081 2Catholics to Rally at USCCB Headquarters in Washington DC Re 3A Healthcare Our Bishops and Abortion 58079 1Catholics to Rally at USCCB Headquarters in Washington DC Re 3A Healthcare Our Bishops and Abortion 58079 2
...HOUSTON -- (Nov. 19, 2008) -- Rice University scie...e stubborn pollutant TCE have created a method tha...ace of a catalyst as individual chemical bonds are...of the bonds between the atoms of our molecules," ... these vibrations change frequency and intensity w...
...MADISON, WI, NOVEMBER 17, 2008 Global land use pat...demand creative urban stormwater management. Tradi... the flow of runoff to waterways, but generally do...d by extensive pavement and compacted urban soils ...portunities affects groundwater recharge and has n...
...BOZEMAN -- The U.S. Department of Energy on Monday...stration Partnership at Montana State University t...f carbon dioxide into the sandstone rock layer ben...third and final phase of federal funding for the B...mately $14 million of the federal money will stay ...
Other Biology News:Researchers shed new light on catalyzed reactions 2Researchers shed new light on catalyzed reactions 3Urban trees enhance water infiltration 2Montana State partnership receives $66.9M for carbon sequestration 2Montana State partnership receives $66.9M for carbon sequestration 3
(Date:11/23/2009)...v. 23, 2009 In a provocative new study, a Univers...oxide emissions the major cause of global warming...collapses or society builds the equivalent of one ...nlikely that there will be any substantial near-te...n carbon dioxide emission rates," says the new pap...
(Date:11/23/2009)...N,Nov.23/PRNewswire-FirstCall/-YMBioSciencesInc.(N...entcompanythatidentifiesandadvancesadiverseportfol...ofdevelopment,todayreportedthatCytopia(ASX:CYT)has...87,apotent,orally-administeredJAK1/JAK2inhibitor.T...nesota.AproposaltomergeCytopiaintoYMhasbeenpreviou...
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire/--Frost&Sullivan,theG...fordemonstratingleadershipandinnovationThursday,No...AwardsBanquetheldinSanAntonio,Texas. ,, (Logo: ...O ) ,, TheHealthcareInnovationAwardsaregiventoc...eliveryandmanagementofhealthcare.Suchcompanieshave...
(Date:11/20/2009)... Nov. 20 Veridiam (www.veridiam.co...ze company category at the 2009 Workplace Excellen...go Society for Human Resources Management and reco...ractices. ,, Veridiam was one of nine winners, ...panies, honored at the recent awards ceremony. San...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2
...PRNewswire-FirstCall/ - Victhom Human Bionics Inc....ing of its updated corporate Website at www.victh... highlights advances in the Company,s two operatin...mplantable neurostimulation device for gait disord...cturing computerized prostheses for above-knee amp...
..., Jan. 9 Schering-Plough Corporation (NYSE: SGP...tion by Thomas P. Koestler, Ph.D., executive vice ...Institute, at the 27th Annual J.P. Morgan Healthca... at approximately 3:30 p.m. (PST) (6:30 p.m. EST).... R&D pipeline and select projects in developme...
... TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Jan....oday that GSK has resubmitted the New Drug Applica...n (FDA) requesting approval of Solzira (TM) (gaba...he treatment of moderate-to-severe primary Restles...d that the data in a single study be reformatted. ...
Other Biology Technology:Victhom Announces Launch of Enhanced Company Website 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3
Acrylamide from GE Healthcare, formerly Amersham Biosciences
Assay Diluent Trial Pack from BioFX Laboratories, Inc.
...lone/PAD: ZMD.474. Immunogen: Synthetic peptide d...ophilin-3. Specificity: Specific for the internal...y: Mouse (positive controls: mouse brain homogenat...pplications: Western blotting Immunohistochemistry...
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
Biology Products: